Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records
JUN 4, 20259 MIN
Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records
JUN 4, 20259 MIN
Description
<p>Attention deficit hyperactivity disorder, or ADHD, is a common condition that, for a lot of people, is difficult to treat. The drugs that exist have a number of adverse side effects, and about 25 percent of patients don’t respond to existing drugs. And so a team of researchers in Iceland, led by Karl Karlsson, professor of biomolecular engineering at Reykjavik University, undertook a number of different steps to narrow in on and then test what the team has determined to be a novel treatment for ADHD, using an existing drug, amlodipine. </p><br><p>Read the full study here: https://www.nature.com/articles/s41386-025-02062-x</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>